Verseau is focused on developing the next major wave of cancer immunotherapies directed at a broad and potent reprogramming of the tumor microenvironment to attack tumors. This is accomplished by stimulating macrophages to shift their phenotype from immunosuppressive to a pro-inflammatory, anti-tumor state in a process called macrophage repolarization. Verseau developed a unique target discovery engine that leveraged patient data and computational biology to discover and validate over 20 novel macrophage targets. Verseau’s first-in-class monoclonal antibody candidates, VTX-0811 targeting PSGL-1 and VTX-1218 targeting VSIG4, are in late preclinical development and progressing toward clinical trials.
Company Details
- Employees
- 6
- Founded
- -
- Address
- 47 Wiggins Ave, Bedford,massachusetts 01730,united States
- in****@****utx.com
- Industry
- Biotechnology Research
- NAICS
-
Research and Development in Biotechnology (except Nanobiotechnology)
- Website
- verseautx.com
- HQ
- Bedford, Massachusetts
Verseau Therapeutics Questions
Verseau Therapeutics's website is verseautx.com
Verseau Therapeutics's LinkedIn profile is https://www.linkedin.com/company/verseautx
Verseau Therapeutics has
6 employees.
View email and phone details for 6
employees at Verseau Therapeutics.
Verseau Therapeutics's industry is
Biotechnology Research
Verseau Therapeutics's top competitors are
Go Therapeutics,
Neurona Therapeutics,
Pyxis Oncology,
Velvet Therapeutics,
Voro Therapeutics,
Nextpoint Therapeutics, Inc.,
Curve Therapeutics,
Jounce Therapeutics, Inc.,
Verséa Health,
Latigo Biotherapeutics, Inc..
Verseau Therapeutics's support email address is info@verseautx.com
Verseau Therapeutics's categories are Biotechnology Research
Verseau Therapeutics's founding year is 2017
